Our findings highlight the NSUN2-YBX1-QSOX1 axis as candidate biomarkers for the prognosis and treatment of NSCLC patients with intrinsic resistance to EGFR-TKIs. This evidence concerns the gene NSUN2 and non-small cell lung carcinoma.